Zifo published an insight piece on April 21, 2026, highlighting that AI in biopharma fails without proper scientific context due to fragmented and poorly described data.15
AI investments are accelerating in discovery, development, and manufacturing, but data lacks the context needed for meaningful use, leading to rework, repeated experiments, and stalled initiatives.12
Data stewardship is essential to preserve scientific intent, ensuring clarity, traceability, and accountability for scaling AI confidently.15
Becoming AI-ready requires a layered foundation:
trusted data (accurate, attributable, traceable), FAIR enhancements (semantic alignment, standardized terminologies), and human oversight for accountability.15
The insight is authored by Zifo Data Stewardship Practice Lead, Marilyne Labasque, PhD.1
Sources:
1. https://www.prnewswire.com/news-releases/biopharma-companies-encounter-ais-weak-spot-scientific-context-says-zifo-302748689.html
2. https://bcbn.org/boston-cambridge-biotech-news/2026/04/21/biopharma-companies-encounter-ais-weak-spot-scientific-context-says-zifo/
5. https://zifornd.com/blogs/biopharma-companies-discover-ais-weak-spot-scientific-context/